The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al.

Currently this strategy is proposed by some teams in France, but is not recommended internationally.

The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.

Inclusion criteria:

• Adult subject (≥ 18 years old)
• Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
• Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024

Exclusion criteria:

• Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.

Adult subject (≥ 18 years old) living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg and having benefited from intermittent triple therapy